missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Invitrogen™ ZNRF1 Polyclonal Antibody

Rabbit Polyclonal Antibody
Brand: Invitrogen™ PA5103824
This item is not returnable.
View return policy
Description
Antibody detects endogenous levels of total ZNRF1.
E3 ubiquitin-protein ligase that mediates the ubiquitination of AKT1 and GLUL, thereby playing a role in neuron cells differentiation. Plays a role in the establishment and maintenance of neuronal transmission and plasticity. Regulates Schwann cells differentiation by mediating ubiquitination of GLUL. Promotes neurodegeneration by mediating 'Lys-48'-linked polyubiquitination and subsequent degradation of AKT1 in axons: degradation of AKT1 prevents AKT1-mediated phosphorylation of GSK3B, leading to GSK3B activation and phosphorylation of DPYSL2/CRMP2 followed by destabilization of microtubule assembly in axons (Probable).
Specifications
| ZNRF1 | |
| Polyclonal | |
| Unconjugated | |
| ZNRF1 | |
| B830022L21Rik; E3 ubiquitin-protein ligase ZNRF1; MGC101991; nerve injury gene 283; nerve injury-induced gene 283 protein; Nin283; peripheral nerve injury protein nin283; ring finger protein 42; RING-type E3 ubiquitin transferase ZNRF1; Rnf42; zgc:77896; zinc and ring finger 1; zinc and ring finger 1, E3 ubiquitin protein ligase; zinc and ring finger protein 1; zinc ring finger protein 1; zinc/RING finger protein 1; ZNRF1; Zrfp1 | |
| Rabbit | |
| Affinity chromatography | |
| RUO | |
| 170737, 690769, 84937 | |
| -20°C | |
| Liquid |
| Immunohistochemistry (Paraffin), Western Blot, Immunocytochemistry | |
| 1 mg/mL | |
| PBS with 50% glycerol and 0.02% sodium azide; pH 7.4 | |
| Q8ND25, Q91V17 | |
| ZNRF1 | |
| A synthesized peptide derived from human ZNRF1(Accession Q8ND25), corresponding to amino acid residues P129-K179. | |
| 100 μL | |
| Primary | |
| Human, Mouse, Rat | |
| Antibody | |
| IgG |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction